On Friday, Shares of Royal Dutch Shell plc (ADR) (NYSE:RDS.A), gained 0.72% to $47.32.
Shell (RDS-A)(RDS-B), provided an update on the Burger J exploration well, located in Alaska’s Chukchi Sea. The Burger J well is about 150 miles from Barrow, Alaska, in about 150 feet of water. Shell safely drilled the well to a total depth of 6800 feet this summer in a basin that demonstrates many of the key attributes of a major petroleum basin. For an area equivalent to half the size of the Gulf of Mexico, this basin remains substantially under-explored.
Shell has found indications of oil and gas in the Burger J well, but these are not sufficient to warrant further exploration in the Burger prospect. The well will be sealed and abandoned in accordance with U.S. regulations.
“The Shell Alaska team has operated safely and exceptionally well in every aspect of this year’s exploration program,” said Marvin Odum, Director, Shell Upstream Americas. “Shell continues to see important exploration potential in the basin, and the area is likely to ultimately be of planned importance to Alaska and the US. However, this is a clearly disappointing exploration outcome for this part of the basin.”
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids.
Shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), declined -15.60% to $0.460, during its last trading session.
ImmunoCellular Therapeutics, declared that the governing Board of the California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, has awarded the Company $19.9 million to support the ICT-107 phase 3 registration trial in patients with newly diagnosed glioblastoma. The $19.9 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107 qualified for grant consideration on the basis of being specifically engineered as an immunotherapy that preferentially targets and kills cancer tumor stem cells with the aim of preventing tumor recurrence following standard-of-care treatment.
ImmunoCellular is on track to initiate the phase 3 ICT-107 trial in the fourth quarter of 2015, which will comprise about 120 clinical sites in the US, Europe and Canada, and will recruit about 400 patients. ImmunoCellular has reached agreement with the US FDA on a Special Protocol Assessment (SPA) relative to the primary and secondary endpoints in addition to the statistical plan for the phase 3 trial. The $19.9 million CIRM grant funds will be received by the Company over the duration of the trial as specified milestones are achieved.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate comprises ICT-107, a dendritic cell (DC) vaccine that accomplished Phase II testing trials for the treatment of glioblastoma multiforme (GBM).
At the end of Friday’s trade, Shares of Key Energy Services, Inc. (NYSE:KEG), gained 6.11% to $0.556.
Key Energy Services, will present at the Johnson Rice 2015 Energy Conference, Wednesday, September 30, 2015 in New Orleans, LA.
Dick Alario, Key’s Chief Executive Officer, is planned to present at 9:30 a.m. CDT. The presentation will be available via a live webcast. To access the webcast and slide presentation, go to www.keyenergy.com, select “Investor Relations” and click on the menu titled “Forthcoming Events”.
Key Energy Services, Inc. operates as an onshore rig-based well servicing contractor in the United States and internationally. It offers rig-based services, counting the maintenance, workover, and recompletion of existing oil wells; completion of newly-drilled wells; and plugging and abandonment of wells at the end of their lives, in addition to specialty drilling services to oil and natural gas producers.
Finally, Darden Restaurants, Inc. (NYSE:DRI), ended its last trade with -0.99% loss, and closed at $70.75.
Darden Restaurants, declared a regular quarterly cash dividend of $0.55 per share on the Company’s outstanding common stock. The dividend is payable on November 2, 2015 to shareholders of record at the close of business on October 9, 2015.
Darden Restaurants, Inc., through its auxiliaries, owns and operates full-service restaurants in the United States and Canada. As of July 8, 2015, it owned and operated about 1,500 restaurants under the Olive Garden, LongHorn Steakhouse, Bahama Breeze, Seasons 52, The Capital Grille, Eddie V’s, and Yard House brand names. The company was founded in 1968 and is headquartered in Orlando, Florida.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
